The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
The placebo response is a major issue in clinical trials for psychiatric disorders. Possible contributing factors to this problem include diagnostic misclassification, issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to change, measurement errors, poor quality of data entry and verification, waxing and waning of the natural course of illness, regression toward the mean phenomenon, patient and clinician expectations about the trial, study design issues, non-specific therapeutic effects, and high attrition. Over the past few decades, researchers have attempted to reduce the placebo effect in a variety of ways. Unfortunately, approaches with very little or no benefit have included restricting enrollment to selected populations, rater training, requirement of same rater, and placebo lead-in phases. Some benefits, although often marginal, have been derived from standardizing diagnostic procedures, managing clinicians’ overestimation of change, simplification of study visits and assessments, minimizing non-specific, therapeutic effects, extending trial duration, reducing number of sites, increasing the sensitivity of outcome measures, and reducing the number of treatment arms. Thus far, there has been no attempt to develop new study designs aimed at reducing the placebo effect. We are proposing a novel study design, called ‘Sequential Parallel Comparison Design’, suitable for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for such trials. Its usefulness in clinical research needs to be tested empirically. If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [162]
Citations
Cites
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“These numbers are even more impressive as most negative trials are typically unpublished, suggesting that the average placebo response rate in MDD trials is probably closer to the 35–45p range.Similarly, in smoking cessation trials, the placebo response rate has progressively increased. For example, in a recent study…”
ResultIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
A Primer on Regression Artifacts
Campbell, D. T., & Kenny, D. A. (1999) · Medical Entomology and Zoology · Cited by 482
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Linear Statistical Inference and its Applications.
Moore, P. G., & Rao, C. R. (1967) · The Statistician · doi:10.2307/2987205 · Cited by 439
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427 · cited 1×
“Another useful approach is to use outcome measures that can be administered in both clinician- and patient-rated forms, as in the case of the Inventory of Depressive Symptomatology (IDS) [”
MethodThe Hamilton Depression Scale: EVALUATION OF OBJECTIVITY USING LOGISTIC MODELS
Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00676.x · Cited by 425
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
Research works printed but not linked: 2
- 10.1001/jama.271.24.1940 · doi:10.1001/jama.271.24.1940 · Paper page
- 10.1037//0022-006x.70.4.887 · doi:10.1037//0022-006x.70.4.887
Cited by
Items 101–200 of 460
A discussion on the role of clinimetrics and the misleading effects of psychometric theory
Fava, G. A., & Belaise, C. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.12.006 · Cited by 54
“Not surprisingly, in clinical trials, simple one-item global scales, which offer a clinical synthesis of heterogeneous components, often discriminate better than complex multiitem tools [12,29].”
BackgroundInfluentialKent, J. M., Daly, E., Kezic, I., Lane, R., Lim, P., De Smedt, H., De Boer, P., Van Nueten, L., Drevets, W. C., & Ceusters, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.009 · Cited by 53
Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks
Fava, G. A., Tomba, E., & Bech, P. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000458458 · Cited by 52
Rutherford, B. R., Sneed, J. R., Tandler, J. M., Rindskopf, D., Peterson, B. S., & Roose, S. P. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.04.004 · Cited by 51
Mofsen, A. M., Rodebaugh, T. L., Nicol, G. E., Depp, C. A., Miller, J. P., & Lenze, E. J. (2019) · JMIR Mental Health · doi:10.2196/11845 · Cited by 51
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 54
“Single-dimensional subscale scores may better reflect efficacy [147]) and additional efficacy indicators such as response and remission rates and the number needed to treat seem to be useful (see Sect.”
BackgroundMechanisms of the placebo effect in pain and psychiatric disorders
Holmes, R. D., Tiwari, A. K., & Kennedy, J. L. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.15 · Cited by 56
Leuchter, A. F., Morgan, M. L., Cook, I. A., Dunkin, J. J., Abrams, M., & Witte, E. A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1919-2 · Cited by 53
“…this interaction with the subjects was not substantially different from the support offered to subjects in most antidepressant clinical trials, it may have helped engender the placebo response in these subjects (Fava et al. 2003) and could limit the generalizability of the findings of this study.”
BackgroundResultInfluentialTrivedi, M. H., South, C. C., Jha, M. K., Rush, A. J., Cao, J., Kurian, B. T., Phillips, M. L., Pizzagalli, D. A., Trombello, J. M., Oquendo, M. A., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491093 · Cited by 50
Correll, C. U., Kishimoto, T., & Kane, J. M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/ccorrell · Cited by 54
Escitalopram: Superior to Citalopram or a Chiral Chimera?
Svensson, S. A., & Mansfield, P. R. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000074435 · Cited by 47
Approval of esketamine for treatment-resistant depression
Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30533-4 · Cited by 46
Merlo‐Pich, E., Alexander, R., D, M. F. M., & Goméni, R. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.159 · Cited by 46
Mathew, S. J., Gueorguieva, R. V., Brandt, C., Fava, M., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.106 · Cited by 47
“The two-stage SPCD design provided sufficient power to detect a moderate effect of riluzole with a substantially lower number of patients than a conventional parallel-group addon study and may mitigate the placebo response rate.”
MethodInfluentialA Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials
Zilcha‐Mano, S., Roose, S. P., Brown, P. J., & Rutherford, B. R. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.01.001 · Cited by 46
“The fact that high placebo response hinders the development and eventual approval of new antidepressants has led most pharmaceutical companies and academic researchers to undertake initiatives aimed at reducing placebo response (9-11).”
BackgroundIvanova, A., & Tamura, R. (2011) · Statistical Methods in Medical Research · doi:10.1177/0962280211431023 · Cited by 44
“q11 2 ð1 q2Þ 12p42 3 ð1 p3Þ 43q32 3 ð1 q3Þ n33sn11þn12þn21þn22 2 ð1 s2Þ n1þn2 n13 n23 n11 n12 n21 n22 sn32þn33þn42þn43 3 ð1 s3Þ n3þn4 n31 n41 n32 n33 n42 n43 : 874 Statistical Methods in Medical Research 24(6)”
BackgroundMethodInfluentialGaudiano, B. A., & Herbert, J. D. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082022 · Cited by 43
Baek, J. H., Heo, J.-Y., D, M. F. M., Mischoulon, D., Choi, K. W., Na, E. J., Cho, H., & Jeon, H. J. (2018) · Journal of Ginseng Research · doi:10.1016/j.jgr.2018.03.001 · Cited by 43
“Expectations of a trial outcome [19] and treatment received [20] are likely to have a significant effect on the degree of placebo response.”
BackgroundDretsch, M. N., Johnston, D. T., Bradley, R. S., MacRae, H., Deuster, P. A., & Harris, W. S. (2014) · Military Medicine · doi:10.7205/milmed-d-13-00395 · Cited by 44
A small n sequential multiple assignment randomized trial design for use in rare disease research
Tamura, R., Krischer, J. P., Pagnoux, C., Micheletti, R. G., Grayson, P. C., Chen, Y., & Merkel, P. A. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.11.010 · Cited by 47
“Trial Description In psychiatric diseases, the sequential parallel design [9]is used to augment the placebo controlled trial with a second stage in which placebo non-responders are re-randomized to drug or placebo.”
MethodEisenlohr-Moul, T. A., Girdler, S. S., Johnson, J. L., Schmidt, P. J., & Rubinow, D. R. (2017) · Depression and Anxiety · doi:10.1002/da.22673 · Cited by 42
“Many factors known to be associatedwith high placebo response rates may be relevant to the outcome of the present trial (Fava et al., 2003; Price, Finniss, & Benedetti, 2008), including the following: the high face validity of a hormonal treatment for premenstrual symptoms, which may enhance…”
BackgroundInnovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy
Fava, G. A., Tomba, E., & Tossani, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.014 · Cited by 41
“However, currently, in testing drug treatments in psychiatry the likelihood of failed or inconclusive treatment studies appears to be particularly high (Fava et al., 2003; Otto and Nierenberg, 2002) and one may wonder whether these results may be due to lack of consideration of treatment history in their design, strat…”
Burt, T., Button, K. S., Thom, H. H. Z., Noveck, R. J., & Munafo, M. R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12478 · Cited by 46
Pedrelli, P., Iovieno, N., Vitali, M., Tedeschini, E., Bentley, K. H., & Papakostas, G. I. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c0adf · Cited by 40
“6%(1) and is often associated with a significant financial and psychosocial burden.(2) Substance-use disorders often co-occur with MDD and DD, with the presence of comorbidity worsening the outcome of either disorder.”
BackgroundComparison of Test Statistics for the Sequential Parallel Design
Huang, X., & Tamura, R. (2010) · Statistics in Biopharmaceutical Research · doi:10.1198/sbr.2010.08015 · Cited by 39
“These recommendations were reviewed by Fava et al. (2003); they also proposed the use of a novel study design called the sequential parallel design. The sequential parallel design has two phases of treatment. The first phase involves randomization to placebo and drug and the second phase utilizes the efficacy informat…”
BackgroundMethodInfluentialTestosterone and Libido in Surgically and Naturally Menopausal Women
Alexander, J. L., Dennerstein, L., Burger, H., & Graziottin, A. (2006) · Women s Health · doi:10.2217/17455057.2.3.459 · Cited by 44
“Fava and colleagues, among others, have theorized that the placebo response is not sustained, therefore the longer the study the greater the chance that the treatment will discriminate from placebo [53].”
BackgroundReddy, V. P., Kozielska, M., Johnson, M. G., Vermeulen, A., de Greef, R., Liu, J., Groothuis, G. M. M., Danhof, M., & Proost, J. H. (2011) · Clinical Pharmacokinetics · doi:10.2165/11590590-000000000-00000 · Cited by 38
“[22] Approximately 50% of recent central nervous system (CNS) clinical trials failed to show statistical superiority of the drug over placebo, due to the variable placebo response (20–70%).[23,24] The trend of placebo responses in antipsychotic trials over the last two decades is shown in figure 4.”
BackgroundSmith, S. M., Fava, M., Jensen, M. P., Mbowe, O. B., McDermott, M. P., Turk, D. C., & Dworkin, R. H. (2020) · Pain · doi:10.1097/j.pain.0000000000001849 · Cited by 41
“veloped to reduce placebo group improvements and thereby increase assay sensitivity in RCTs of antidepressant medications.(29,30) In the most common version, patients are first”
BackgroundInfluentialAdvances in designs for Alzheimer's disease clinical trials.
Cummings, J. L., Gould, H. P., & Zhong, K. (2012) · Europe PMC (PubMed Central) · Cited by 48
A big data approach to the development of mixed‐effects models for seizure count data
Tharayil, J., Chiang, S., Moss, R., Stern, J. M., Theodore, W. H., & Goldenholz, D. M. (2017) · Epilepsia · doi:10.1111/epi.13727 · Cited by 37
Mallinckrodt, C. H., Tamura, R., & Tanaka, Y. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.03.001 · Cited by 36
“Several publications have investigated efficiency of the SPD compared to the traditional design (Fava et al., 2003; Tamura and Huang, 2007; Huang and Tamura, 2010).”
ResultTriple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)
Skolnick, P., & Basile, A. S. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363285 · Cited by 40
Dichtel, L. E., Carpenter, L. L., Nyer, M., Mischoulon, D., Kimball, A., Deckersbach, T., Dougherty, D. D., Schoenfeld, D., Fisher, L. B., Cusin, C., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080844 · Cited by 36
Self-citationHirayasu, Y., Sato, S., Takahashi, H., Iida, S., Shuto, N., Yoshida, S., Funatogawa, T., Yamada, T., & Higuchi, T. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0778-9 · Cited by 36
“This is partly because definite placebo effects were repeatedly reported in the variety of clinical studies where compounds for the treatments of various types of psychiatric disorders were included [30].”
BackgroundSTAR*D: A Tale and Trail of Bias
Pigott, H. (2011) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.13.1.6 · Cited by 25
Importance of Placebo Effect in Cough Clinical Trials
Eccles, R. (2009) · Lung · doi:10.1007/s00408-009-9173-3 · Cited by 35
“The problem of a large placebo response is apparent in most clinical trials on psychiatric medicines because the great majority of these trials fail to demonstrate that any pharmacological treatment is superior to placebo treatment; this has led to a search for new clinical trial designs in this area to control the pl…”
BackgroundVeraart, J. K. E., van Westenbrugge, M., Palthe, J. E. V. W., van der Meij, A., Schoevers, R. A., & de Jong, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15883 · Cited by 33
Biederman, J., Lindstén, A., Sluth, L. B., Petersen, M. L., Ettrup, A., Eriksen, H. F., & Fava, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119832538 · Cited by 33
Zajecka, J., Stanford, A. D., Memisoglu, A., Martin, W. F., & Pathak, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199245 · Cited by 34
“The strategy of SPCD is to enhance signal detection in the presence of placebo response and obtain greater statistical power with fewer patients compared with the placebo run-in approach used in FORWARD-3.”
BackgroundMethodInfluentialBrown, H. E., Freudenreich, O., Fan, X., Heard, S. O., GOFF, D. C., Petrides, G., Harrington, A., Kane, J. M., Judge, H., Hoeppner, B. B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0151 · Cited by 33
The Decline of Pharmaceutical Psychiatry and the Increasing Role of Psychological Medicine
Fava, G. A. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000214443 · Cited by 36
AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation
Khoury, R., Marx, C., Mirgati, S., Velury, D., Chakkamparambil, B., & Grossberg, G. T. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882995 · Cited by 32
Estimation of treatment effect for the sequential parallel design
Tamura, R., Huang, X., & Boos, D. D. (2011) · Statistics in Medicine · doi:10.1002/sim.4412 · Cited by 32
“[2] proposed a weighted sum of the observed treatment differences over the two phases to test the null hypothesis of no treatment effect in either the overall or the subpopulation of placebo non-responders.”
BackgroundMethodInfluentialThe evolving randomised controlled trial in mental health: studying complexity and treatment process
Green, J. (2006) · Advances in Psychiatric Treatment · doi:10.1192/apt.12.4.268 · Cited by 35
“…open enquiry is the contemporary guarantor of robust and stable social knowledge within a plethora of easily accessible opinion (Theodosiou & Green, 2003), it can be argued that engaging in research to help generate such knowledge is a social duty rather than something from which to be…”
BackgroundD, M. F. M., Freeman, M. P., Flynn, M., Hoeppner, B. B., Shelton, R. C., Iosifescu, D. V., Murrough, J. W., Mischoulon, D., Cusin, C., Rapaport, M. H., et al. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.09.010 · Cited by 32
“Methods—Eighty-four eligible subjects with TRD were randomly assigned to double-blind treatment with LFMS 20 minutes/day for four days, sham treatment 20 minutes/day for four days, or sham treatment 20 minutes/day for 2 days followed by LFMS treatment 20 minutes/day for two days, using the pre-randomization version of…”
MethodWalco, G. A., Kopecky, E. A., Weisman, S. J., Stinson, J., Stevens, B., Desjardins, P. J., Berde, C. B., Krane, E. J., Anand, K. J. S., Yaster, M., et al. (2017) · Pain · doi:10.1097/j.pain.0000000000001104 · Cited by 37
“Adaptive trial designs and the sequential parallel comparison design that have been used with adults aim to conserve patient numbers or yield more robust results [24] but have not been deployed with children and adolescents.”
BackgroundTomba, E. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000334112 · Cited by 34
Dünner, D. L., Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., & Fava, M. (2005) · Current Therapeutic Research · doi:10.1016/j.curtheres.2005.12.003 · Cited by 31
Schindler, A. C., Hiller, W., & Witthöft, M. (2011) · Psychotherapy Research · doi:10.1080/10503307.2011.602750 · Cited by 34
Can knowledge of Placebo and Nocebo Mechanisms Help Improve Randomized Clinical Trials?
Carlino, E., & Vase, L. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.01.012 · Cited by 34
Tolerability and Safety of Transcranial Photobiomodulation for Mood and Anxiety Disorders
Cassano, P., Norton, R., Caldieraro, M. A., Vahedifard, F., Vizcaino, F., McEachern, K. M., & Iosifescu, D. V. (2022) · Photonics · doi:10.3390/photonics9080507 · Cited by 30
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
Ylescupidez, A., Bahnson, H. T., O’Rourke, C., Lord, S. M., Speake, C., & Greenbaum, C. J. (2023) · Nature Communications · doi:10.1038/s41467-023-42581-z · Cited by 30
“4) 39 , are also feasible.”
Wang, G., Mcintyre, A., Earley, W., Raines, S., & Eriksson, H. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50248 · Cited by 27
Zajecka, J., D, M. F. M., Shelton, R. C., Barrentine, L. W., Young, P., & Papakostas, G. I. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10181 · Cited by 30
Targum, S. D., Wedel, P. C., Robinson, J. O., Daniel, D. G., Busner, J., Bleicher, L. S., Rauh, P., & Barlow, C. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.02.016 · Cited by 30
Traditional and Innovative Experimental and Clinical Trial Designs and Their Advantages and Pitfalls
Weimer, K., & Enck, P. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44519-8_14 · Cited by 32
Hyde, A. J., May, B. H., Xue, C. C., & Zhang, A. L. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.02.022 · Cited by 29
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. N., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0274-7 · Cited by 30
“We have noted nonspecific therapeutic improvements in RCTs that have also occurred, associated with an increasing intensity of study-related clinical management processes [51].”
When should the sequential parallel comparison design be used in clinical trials?
Baer, L., & Ivanova, A. (2013) · Clinical Investigation · doi:10.4155/cli.13.74 · Cited by 28
Wilsey, B. L., Deutsch, R., & Marcotte, T. D. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0016 · Cited by 32
“Unfortunately, attempts to restrict clinical trials to populations with greater illness severity have typically failed.(23) There is no experience with this design using cannabinoids, but the prospect of using participants with a higher baseline pain would seem to be a feasible goal in”
BackgroundDoes accounting for seizure frequency variability increase clinical trial power?
Goldenholz, D. M., Goldenholz, S. R., Moss, R., French, J. A., Lowenstein, D. H., Kuzniecky, R., Haut, S. R., Cristofaro, S., Detyniecki, K., Hixson, J., et al. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.07.013 · Cited by 28
When Expectancies Are Violated: A Functional Magnetic Resonance Imaging Study
Colloca, L., Schenk, L. A., Nathan, D. E., Robinson, O. J., & Grillon, C. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1587 · Cited by 28
Is it Easier to Find What You Are Looking for if You Think You Know What it Looks Like?
Mundt, J. C., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., DeBrota, D. J., Chappell, P. B., & Modell, J. G. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3180387820 · Cited by 29
“Alternative study designs and the use of computer technologies to assess patients directly have been suggested to address such problems.(2,3) Computer-automated interviews for obtaining patient-reported information have been researched for more than 40 years.”
BackgroundSanten, G. W. E., Horrigan, J. P., Danhof, M., & Pasqua, O. E. D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.107 · Cited by 27
Relationship between placebo response rate and clinical trial outcome in bipolar depression
Iovieno, N., Nierenberg, A. A., Parkin, S. R., Kim, D. J. H., Walker, R. S. W., D, M. F. M., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.12.016 · Cited by 27
Papakostas, G. I., Johe, K. K., Hand, H., Drouillard, A., Russo, P. A., Kay, G. G., Kashambwa, R., Hoeppner, B. B., Flynn, M., Yeung, A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0334-8 · Cited by 27
“…adequate dose and duration during the current major depressive episode as defined by the MGH Antidepressant Treatment History Questionnaire (MGHATRQ; Fava, 2003 [34]) and administered both by site investigators and MGH CTNI raters remotely (meeting this criterion during either assessment was…”
MethodHow should we design future mechanistic and/or efficacy clinical trials?
D, M. F. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01600-9 · Cited by 27
“…standard comparator in the study design, general knowledge of the ef fi cacy of the study treatments, positive regard toward the institution(s) where the study is carried out or toward the study clinicians, and underlying cultural assumptions that biological/device/drug treatments are effective [8].”
BackgroundMethodInfluentialOn clinical trials with a high placebo response rate
Chi, G. Y. H., Li, Y., Liu, Y., Lewin, D., & Lim, P. (2015) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2015.10.002 · Cited by 26
Simen, A. A., Whitlock, M., Qiu, R., Miceli, J. J., Zumpano, L., Metz, M. D., Dua, P., & Binneman, B. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000997 · Cited by 28
Motta, L. S., Gosmann, N. P., Costa, M. D. A., Jaeger, M. D. B., Frozi, J., Grevet, L. T., Spanemberg, L., Manfro, G. G., Cuijpers, P. J., Pine, D. S., et al. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2022-300630 · Cited by 25
Matsingos, A., Wilhelm, M., Noor, L., Yildiz, C., Rief, W., Hofmann, S. G., Falkenberg, I., & Kircher, T. T. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1346697 · Cited by 27
Gostoli, S., Roncuzzi, R., Urbinati, S., & Rafanelli, C. (2017) · Applied Psychology Health and Well-Being · doi:10.1111/aphw.12098 · Cited by 27
Drug‐Placebo Additivity in Randomized Clinical Trials
Hall, K. T., & Loscalzo, J. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1626 · Cited by 25
Herzog, P., Voderholzer, U., Gärtner, T., Osen, B., Svitak, M., Doerr, R., Rolvering-Dijkstra, M., Feldmann, M., Rief, W., & Brakemeier, E. (2020) · Psychotherapy Research · doi:10.1080/10503307.2020.1802081 · Cited by 26
“However, using simple one-time global scales may be useful, given that the clinical synthesis of heterogeneous components seems often to discriminate better than complex multi-item measures (Fava et al., 2003).”
BackgroundSachs, G. S., Vanderburg, D. G., Edman, S., Karayal, O. N., Kolluri, S., Bachinsky, M., & Çavuş, I. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07389 · Cited by 24
Ghaemi, S. N., & Selker, H. P. (2017) · Journal of Clinical and Translational Science · doi:10.1017/cts.2017.2 · Cited by 24
“Some investigators have even proposed extending the RDT approach from maintenance studies to acute trials in psychiatry [18].”
BackgroundWilkinson, S. T., Kiselycznyk, C., Banasr, M., Webler, R. D., Haile, C. N., & Mathew, S. J. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.075 · Cited by 27
“Using a sequential, parallel comparison design [34], subjects (n=104) were randomized (2:3:3) to 8 weeks of riluzole, 8 weeks of placebo, or 4 weeks of placebo followed by 4 weeks of riluzole.”
MethodPsychological Factors Affecting Functional Gastrointestinal Disorders
Porcelli, P., & Todarello, O. (2007) · KARGER eBooks · doi:10.1159/000106796 · Cited by 23
Fisher, L. B., D, M. F. M., Doros, G. D., Alpert, J. E., Henry, M. W., Huz, I., & Freeman, M. P. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000364 · Cited by 24
“The sequential parallel comparison design method (Fava et al., 2003) divided the trial into two 30-day phases, with assessments performed every 10 days.”
MethodWhy Are Innovative Drugs Failing in Phase III?
Marder, S. R., LAUGHREN, T. P., & Romano, S. J. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040426 · Cited by 22
INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS
Rutherford, B. R., Bailey, V. S., Schneier, F. R., Pott, E., Brown, P. J., & Roose, S. P. (2015) · Depression and Anxiety · doi:10.1002/da.22433 · Cited by 21
“[1, 2] High placebo response rates contribute to diminishing average drug–placebo differences and increasing numbers of failed trials, both of which increase the costs of drug development, delay clinical availability of new medications, and precipitate reductions in pharmaceutical company research for psychiatric diso…”
BackgroundWhitlock, M., Woodward, P. W., & Alexander, R. (2019) · PubMed · Cited by 21
Buprenorphine: prospective novel therapy for depression and PTSD
Madison, C. A., & Eitan, S. (2020) · Psychological Medicine · doi:10.1017/s0033291720000525 · Cited by 24
Defining ‘recovery’ for delirium research: a systematic review
Adamis, D., Devaney, A., Shanahan, E., McCarthy, G. M., & Meagher, D. J. (2014) · Age and Ageing · doi:10.1093/ageing/afu152 · Cited by 21
“As a consequence, in statistical analysis, the regression to the mean will contribute to an invalid finding of clinical improvement [22].”
BackgroundKhan, A., Yavorsky, W. C., Liechti, S., DiClemente, G., Rothman, B., Opler, M. G., DeFries, A., & Jovic, S. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182776ebe · Cited by 21
“In psychiatry, double-blind, placebo-controlled trials that have failed to confirm the superiority of a drug over a placebo are prevalent.(3) Otto and Nierenberg(4) indicate that to assume that a trial has failed owing to unsuccessful assay sensitivity misrepresents the scientific practice, especially when the trial i…”
BackgroundMerlo‐Pich, E., & Goméni, R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.70 · Cited by 21
The Evolving Story of Folate in Depression and the Therapeutic Potential of l -Methylfolate
Nelson, J. C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12091207 · Cited by 21
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20
“We therefore examined the longer-term efficacy of adjunctive riluzole in an open-label extension phase of the multicenter acute-phase double-blind trial that had shown no effects of riluzole in the randomized 8-week sequential parallel comparison design (SPCD) phase (Mathew et al., 2017).”
MethodInfluentialPlacebo non‐response measure in sequential parallel comparison design studies
Rybin, D. V., Doros, G. D., Pencina, M. J., & D, M. F. M. (2015) · Statistics in Medicine · doi:10.1002/sim.6494 · Cited by 20
“[15] After screening, patients were randomized to either aripiprazole–aripiprazole (n = 54), placebo–placebo (n = 83), or placebo– aripiprazole (n = 84) in a 2:3:3 ratio, according to format 2 of SPCD (therefore with pre-randomization rather than re-randomization).[1] The patients were followed for 60 days (30 days in…”
MethodOh, G. H., Yu, J., Choi, K., Joo, E.-J., & Jeong, S.-H. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.1.46 · Cited by 20
Methods for assessing and controlling placebo effects
Kessels, R., Mozer, R., & Bloemers, J. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217748339 · Cited by 20
Interhemispheric Transfer in Alexithymia: A Transcallosal Inhibition Study
Grabe, H. J., Möller, B., Willert, C., Spitzer, C., Rizos, T., & Freyberger, H. J. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000075543 · Cited by 20
Weisler, R. H., Khan, A., Trivedi, M. H., Yang, H., Eudicone, J. M., Pikalov, A., Tran, Q. V., Berman, R. M., & Carlson, B. X. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05495gre · Cited by 19
D, M. F. M., Mazzone, E., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Hock, R. S., Shui, A. M., Macaluso, M., Morrison, M. F., et al. (2020) · Annals of Clinical Psychiatry · doi:10.12788/acp.0003 · Cited by 19
“19 The capacity to detect rapid-onset efficacy of the treatment was a priority in the study design.”
Decoding the impact of the placebo response in clinical trials for chronic cough
Zhang, M., Zhang, B., & Morice, A. H. (2024) · ERJ Open Research · doi:10.1183/23120541.00335-2024 · Cited by 20
“Sequential parallel comparison design (SPCD) and two-way enriched design (TED), an extension of SPCD, can be considered where placebo effect may confound evaluation [101 – 103].”
Sumner, C. R., Haynes, V. S., Teicher, M. H., & Newcorn, J. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2201 · Cited by 20
“Perhaps nowhere are placebo effects of greater clinical consequence than in the sphere of central nervous system (CNS) research, in which benchmarks of efficacy for new therapies are largely subjective, typically obtained through ratings by the very parties (eg, patients, clinicians, caregivers, teachers) who are argu…”
BackgroundHeinzel, S., Schwefel, M., Sánchez, A., Heinen, D., Fehm, L., Henze, R., Terán, C., Kallies, G., Rapp, M. A., Fydrich, T., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.024 · Cited by 21
Early score fluctuation and placebo response in a study of major depressive disorder
Targum, S. D., Cameron, B. R., Ferreira, L., & MacDonald, I. D. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.11.014 · Cited by 18
Salloum, N. C., D, M. F. M., Ball, S., & Papakostas, G. I. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0646-3 · Cited by 18
Lessons to be Learned from Placebo Arms in Psychopharmacology Trials
Doering, B. K., Rief, W., & Petrie, K. J. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44519-8_15 · Cited by 19
Metadata
- Authors
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 72
- Issue
- 3
- Pages
- 115-127
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2073526412
- Cited by
- 452
- References
- 34
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 29 · 2019: 41 · 2018: 23 · 2017: 32 · 2016: 21 · 2015: 29 · 2014: 22 · 2013: 21 · 2012: 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, placebo effect, mental illness, clinical trial design, regression to the mean, attrition, sample size reduction, outcome measure sensitivity
- MeSH terms
- Mental Disorders, Clinical Trials as Topic, Double-Blind Method, Humans, Research Design, Reproducibility of Results, Placebo Effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.